In various cancers, PD-1 can be expressed on tumour infiltrating lymphocytes (TILs), where CD4+ and CD8+ TILs exhibit an increased PD-1 expression on Treg and Tc, effectively resulting in Treg-mediated immunosuppression and Tc anergy/loss of CTL function (36). Here, CD8A is linked to cancer.